BiotechTube
Home/Zealand Pharma/Kirsten Drejer, Ph.D.
KD

Kirsten Drejer, Ph.D.

Deputy Chairperson of the Board

Zealand Pharma

Therapeutic Areas

Metabolic DiseasesGastrointestinal DiseasesEndocrinology

Zealand Pharma Pipeline

DrugIndicationPhase
Survodutide (BI 456906)ObesityPhase 3
Dapiglutide (ZP7570)Short bowel syndrome (SBS)Phase 2
ZP8396ObesityPreclinical/Phase 1
V-Go®Insulin delivery for diabetesCommercial
Dasiglucagon (Zegalogue®)Congenital hyperinsulinism (CHI) / Severe hypoglycemiaApproved
ZP8980Oncology (cachexia)Preclinical

Leadership Team at Zealand Pharma

AS
Adam Steensberg, Ph.D.
President and Chief Executive Officer
MB
Mats Blom
Executive Vice President and Chief Financial Officer
DH
David H. Solomon, M.D.
Executive Vice President and Chief Medical Officer
BM
Bahar M. Brandes, M.D.
Executive Vice President and Chief Development Officer
AV
Allan Valentine
Executive Vice President and General Counsel
LK
Lise Kjærsgaard, Ph.D.
Executive Vice President and Chief Scientific Officer
PT
Pernille T. Madsen
Senior Vice President, Corporate Communications & Investor Relations
BE
Bernhard Ehmer
Chairman of the Board
AM
Alain Munoz
Board Member
JK
Jens Knudsen
Board Member
View full Zealand Pharma profile